Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

• Main Authors: Salini Mohanty (Author), Tianyan Hu (Author), GyongSeon Yang (Author), Tsz K Khan (Author), Kwame Owusu-Edusei (Author), Isaya Sukarom (Author)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA) is a 15-valent PCV currently approved in adults in the United States, co...